Table 3.
Drugs triggered cytokine release syndrome
| Antibody | Antigen | Driven cytokine and approximate time of CRS appearance, and Ref. |
|---|---|---|
| Muromonab | CD3 | TNF-α, IFN-γ, IL-2, and IL-6; 2~4 h after infusion (Yan et al., 2019)55 |
| Rituximab | CD20 | TNF-α, IFN-γ, and IL-6; 2 h after infusion (Byrd et al., 2001)58 |
| TGN1412 | CD28 | TNF-α, IFN-γ, IL-8, IL-10, and DIC; 1.5 h after infusion (Suntharalingam et al., 2006)59 |
| CP-870,893 | CD40 | TNF-α and IL-6; minutes to hours after infusion (Vonderheide et al., 2007;64 and Nowak et al., 2015)63 |
| Alemtuzumab | CD52 | TNF-α, IFN-γ, and IL-6; 2~4 h after infusion (Ferrajoli et al., 2001;65 and Moreau et al., 1996)66 |
| Blinatumomab | CD3 & CD19 | TNF-α and IL-6; no time information (Topp et al., 2015)60 |
| TDB | CD3 & HER2 | TNF-α, IL-1, IL-2, and IL-6; 2 h after infusion (Li et al., 2019)61 |
| Nivolumab & ipilimumab | PD1 & CTLA4 | CRP, aspartate aminotransferase, alanine aminotransaminase, D-dimer; minutes to day 2 after infusion (Urasaki et al., 2021)62 |